Abstract:Repurposing identified Food and Drug Administration‐approved drug‐biomarker combinations with high sensitivity and specificity. In a real‐world dataset, repurposing identified novel drug‐biomarker combinations in patients who were ineligible for standard therapies or biomarker‐matched trials. Preliminary functional validation was demonstrated for two drug‐biomarker combinations. Using The Cancer Genome Atlas data, the potential scope of repurposing was identified. Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. Methods Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO‐500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature. Variants of unknown significance were classified as potentially pathogenic using plausible mechanisms and computational prediction of pathogenicity. Gain of function (GOF) mutations were evaluated through repurposing databases Probe Miner (PM), Broad Institute Drug Repurposing Hub (Broad Institute DRH) and TOPOGRAPH. GOF mutations were repurposing events if identified in PM, not indexed in TOPOGRAPH and excluding mutations with a known Food and Drug Administration (FDA)‐approved biomarker. The computational repurposing approach was validated by evaluating its ability to identify FDA‐approved biomarkers. The total repurposable genome was identified by evaluating all possible gene‐FDA drug‐approved combinations in the PM dataset. Results The computational repurposing approach was accurate at identifying FDA therapies with known biomarkers (94%). Using next‐generation sequencing molecular reports (n = 94), a meaningful percentage of patients (14%) could have an off‐label therapeutic identified. The frequency of theoretical drug repurposing events in The Cancer Genome Atlas pan‐cancer dataset was 73% of the samples in the cohort. Conclusion A computational drug repurposing approach may assist in identifying novel repurposing events in cancer patients with no access to standard therapies. Further validation is needed to confirm a precision oncology approach using drug repurposing.

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

DrugRepoBank: a comprehensive database and discovery platform for accelerating drug repositioning

A drug repurposing method based on inhibition effect on gene regulatory network

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

An Analytical Review of Computational Drug Repurposing

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Drug Repurposing for Cancer Treatment Through Global Propagation with a Greedy Algorithm in a Multilayer Network

Knowledge-driven drug repurposing using a comprehensive drug knowledge graph

DrugSim2DR: systematic prediction of drug functional similarities in the context of specific disease for drug repurposing

A New Approach to Drug Repurposing with Two-Stage Prediction, Machine Learning, and Unsupervised Clustering of Gene Expression

Informatics on Drug Repurposing for Breast Cancer.

Repurposing of Drugs: Updates and New Perspectives

DrugRep: an automatic virtual screening server for drug repurposing

A Computational Strategy for Drug Repositioning Based on Support-Vector Regression Algorithm

Drug Repurposing: An Effective Tool in Modern Drug Discovery

A Method to Capitalise on Prior Drug Discovery Efforts to Highlight Candidate Drugs for Repurposing

Artificial intelligence, machine learning, and drug repurposing in cancer

Drug Repurposing by Integrated Literature Mining and Drug-Gene-Disease Triangulation

Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug Repurposing.

Drug Repositioning By Kernel-Based Integration Of Molecular Structure, Molecular Activity, And Phenotype Data